SCHEMBL6863025

SCHEMBL6863025

CC(O)C(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937118 1.00 MPI (0.35) MPI
Lactic Acid SCHEMBL2582472 0.95 TP53 (0.37) MPI
Glycerin SCHEMBL9351848 0.92 MPI (0.31) MPI
Succinic Acid SCHEMBL4315810 0.92 MPI (0.31) MPI
SCHEMBL424017 0.89 MPI (0.35) MPI
SCHEMBL215097 0.83 MPI (0.36) MPI
SCHEMBL2884877 0.83 MPI (0.36) MPI
SCHEMBL426315 0.83 MPI (0.36) MPI
SCHEMBL13430949 0.83 MPI (0.36) MPI
SCHEMBL8367251 0.83 MPI (0.32) MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4504890-A1 ARTIFICIAL LYMPH NODE BIOREATOR Mirror Biologics, Inc. (US) 2025-02-12 EP claimed
CN-114487168-B Preparation and value setting method of blood lactic acid standard substance 中国计量科学研究院 2024-03-12 CN claimed
WO-2023196391-A1 ARTIFICIAL LYMPH NODE BIOREATOR MIRROR BIOLOGICS, INC. (US) 2023-10-12 WO claimed
US-20230323264-A1 Artificial lymph node bioreactor MIRROR BIOLOGICS, INC. 2023-10-12 US claimed
CN-115969762-A Long-acting high-efficiency moisturizing supermolecule liposome mask and preparation method thereof 深圳市萱嘉生物科技有限公司 2023-04-18 CN claimed
CN-114487168-A Preparation and value determination method of blood lactic acid standard substance 中国计量科学研究院 2022-05-13 CN claimed
US-9890356-B2 Use of G-CSF in in vitro embryo culture SCARPELLINI FABIO (IT) 2018-02-13 US claimed
US-20170363565-A1 Analyte Measurement INSIDE BIOMETRICS INTERNATIONAL LIMITED (GB) 2017-12-21 US claimed
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF GLIAPHARM SA (CH) 2026-05-07 US disclosed
EP-4728045-A2 MODULAR BIOREACTOR SYSTEMS FOR REGENERATIVE MEDICINE APPLICATIONS Wake Forest University Health Sciences (US) 2026-04-22 EP disclosed
US-20260053860-A1 METHOD OF PROMOTING RETURN OF ESTRUS IN ANIMAL AND AGENT FOR PROMOTING RETURN TO ESTRUS IN ANIMAL ANICOM HOLDINGS, INC. (JP) 2026-02-26 US disclosed
US-20260041818-A1 BIOENGINEERED INTERNAL ANAL SPHINCTER CONSTRUCTS AND METHODS OF USE THEREOF CELLF BIO INC (US) 2026-02-12 US disclosed
US-12533462-B2 Infusion unit INFUZAMED LLC 2026-01-27 US disclosed
US-20250258125-A1 BIOSENSOR AND MANUFACTURING METHOD THEREFOR LEADWAY (HK) LIMITED (CN) 2025-08-14 US disclosed
CN-1134110-A Method for regulating gastrointestinal motility AMYLIN PHARMACEUTICALS INC (US) 1996-10-23 CN disclosed
WO-1996012408-A1 REAGENTS WITH ENHANCED PERFORMANCE IN CLINICAL DIAGNOSTIC SYSTEMS CHIRON DIAGNOSTICS CORPORATION (US) 1996-05-02 WO disclosed
EP-0597033-A1 IGF-1 TO IMPROVE THE NEURAL CONDITION. GENENTECH INC (US) 1994-05-18 EP disclosed
WO-1993002695-A1 IGF-1 TO IMPROVE THE NEURAL CONDITION GENENTECH, INC. (US) 1993-02-18 WO disclosed
EP-0052718-B1 METHOD AND APPARATUS FOR THE DETERMINATION OF SUBSTANCES IN BIOLOGICAL SOLUTIONS BY DIFFERENTIAL PH MEASUREMENT Luzzana, Massimo (IT) 1985-09-11 EP disclosed
EP-0052718-A1 Method and apparatus for the determination of substances in biological solutions by differential pH measurement Luzzana, Massimo (IT) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041818-A1 BIOENGINEERED INTERNAL ANAL SPHINCTER CONSTRUCTS AND METHODS OF USE THEREOF NES, MYH2, MYH10 MPI 3213/4885
US-12533462-B2 Infusion unit TNF, SEC24C, ATP6V1B1 MPI 2522/4885
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF LDHA, PC, LDHB MPI 1870/4885
US-20260053860-A1 METHOD OF PROMOTING RETURN OF ESTRUS IN ANIMAL AND AGENT FOR PROMOTING RETURN TO ESTRUS IN ANIMAL PGF, ALPP, FABP4 MPI 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.